KPCM
ORMP icon

Kings Point Capital Management’s Oramed Pharmaceuticals ORMP Stock Holding History

Kings Point Capital Management’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-500
Closed -$11K – 648
2021
Q3 		$11K Buy
+500
New +$8.52K ﹤0.01% 562

Other funds holding ORMP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Kings Point Capital Management's ORMP Position: Q4 2021 in Review

Kings Point Capital Management sold out of Oramed Pharmaceuticals (ORMP) in Q4 2021, closing a stake of 500 shares — an estimated $11K sold.

Kings Point Capital Management first reported a position in ORMP in Q3 2021 and held it in 1 quarter. The position peaked at $11K in Q3 2021. 116 funds tracked by Wall St. Rank hold ORMP as of Q4 2021.

  • Kings Point Capital Management reported no remaining Oramed Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Kings Point Capital Management sold 500 Oramed Pharmaceuticals shares in Q4 2021, an estimated $11K.
  • Kings Point Capital Management first reported a position in Oramed Pharmaceuticals in Q3 2021 and held it in 1 quarter.
  • Kings Point Capital Management's Oramed Pharmaceuticals position peaked at $11K in Q3 2021.
  • 116 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q4 2021.

Based on Kings Point Capital Management's 13F filing for Q4 2021, filed 11 Feb 2022.